Cobra Biologics Announces Scale-Up Collaboration

September 24, 2015
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 11, Issue 10

Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.

Cobra Biologics and Alan Dickson, professor of biotechnology at The University of Manchester (UoM) announced on Sept. 24, 2015 a two-year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported through the FLexible Interchange Programme (FLIP) Scheme from the Biotechnology and Biological Sciences Research Council (BBSRC). 

The partnership will address the need for greater predictability and certainty in process development and scale-up for the production of protein-based biopharmaceuticals for application in therapeutic areas including cancer and inflammation, according to a Cobra Biologics press announcement.

The agreement will give Cobra access to the UoM’s academic and associated research group. Professor Dickson will have access to Cobra’s production data and operational knowledge of industrial manufacturing processes. Financial terms and terms relating to IP have not been disclosed. 

Source: Cobra Biologics